Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 4.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 217,729 shares of the company’s stock after purchasing an additional 9,458 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned approximately 0.25% of Intellia Therapeutics worth $8,115,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently made changes to their positions in NTLA. MetLife Investment Management LLC raised its position in shares of Intellia Therapeutics by 54.7% during the first quarter. MetLife Investment Management LLC now owns 37,362 shares of the company’s stock valued at $2,715,000 after buying an additional 13,209 shares during the last quarter. Rhumbline Advisers lifted its stake in Intellia Therapeutics by 2.7% in the 1st quarter. Rhumbline Advisers now owns 98,247 shares of the company’s stock worth $7,140,000 after purchasing an additional 2,620 shares in the last quarter. Cibc World Market Inc. boosted its holdings in shares of Intellia Therapeutics by 47.3% during the 1st quarter. Cibc World Market Inc. now owns 4,740 shares of the company’s stock valued at $344,000 after purchasing an additional 1,522 shares during the last quarter. Blair William & Co. IL grew its position in shares of Intellia Therapeutics by 11.9% during the first quarter. Blair William & Co. IL now owns 10,362 shares of the company’s stock valued at $753,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Intellia Therapeutics in the first quarter worth about $307,000. Institutional investors own 88.47% of the company’s stock.
Insider Transactions at Intellia Therapeutics
In other Intellia Therapeutics news, EVP Eliana Clark sold 5,000 shares of the business’s stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. Following the sale, the executive vice president now owns 45,146 shares in the company, valued at approximately $2,031,570. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Intellia Therapeutics news, Director Muna Bhanji sold 1,867 shares of the company’s stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $39.30, for a total value of $73,373.10. Following the transaction, the director now directly owns 12,526 shares of the company’s stock, valued at approximately $492,271.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Eliana Clark sold 5,000 shares of Intellia Therapeutics stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $45.00, for a total value of $225,000.00. Following the sale, the executive vice president now owns 45,146 shares of the company’s stock, valued at $2,031,570. The disclosure for this sale can be found here. In the last three months, insiders sold 7,492 shares of company stock valued at $324,174. Company insiders own 3.00% of the company’s stock.
Intellia Therapeutics Trading Up 2.5 %
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.08). Intellia Therapeutics had a negative net margin of 854.92% and a negative return on equity of 41.64%. The company had revenue of $13.59 million during the quarter, compared to analysts’ expectations of $12.08 million. During the same quarter in the prior year, the business earned ($1.33) EPS. The business’s revenue for the quarter was down 3.1% compared to the same quarter last year. On average, sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.45 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
NTLA has been the subject of several research analyst reports. Canaccord Genuity Group cut their price target on Intellia Therapeutics from $66.00 to $65.00 and set a “buy” rating for the company in a report on Monday. Barclays lowered their price objective on Intellia Therapeutics from $148.00 to $90.00 and set an “overweight” rating for the company in a research note on Friday, August 4th. Citigroup lowered their price target on Intellia Therapeutics from $44.00 to $40.00 and set a “neutral” rating for the company in a research report on Friday, August 4th. BMO Capital Markets increased their price target on Intellia Therapeutics from $57.00 to $64.00 in a report on Friday, May 5th. Finally, StockNews.com started coverage on Intellia Therapeutics in a research note on Thursday, May 18th. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and an average price target of $82.00.
View Our Latest Analysis on Intellia Therapeutics
Intellia Therapeutics Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas.
Featured Stories
- Five stocks we like better than Intellia Therapeutics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 5 Best Fintech Stocks to Buy Now
- 3 Small Caps With Big Return Potential
- UPS Slipping To More Attractive Levels On Weak OutlookÂ
- What is the S&P 500 and How It is Distinct from Other Indexes
- More Good News Coming? GoodRx Spikes Ahead of Q2 Earnings
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
